Last update 11 Jul 2024

Rademikibart

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
Mechanism
IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Eosinophilic AsthmaPhase 3
CN
10 Jul 2024
AsthmaPhase 3
CN
26 Jun 2024
InflammationPhase 2
HU
28 Apr 2021
Persistent asthmaPhase 2
PL
28 Apr 2021
Persistent asthmaPhase 2
UA
28 Apr 2021
Persistent asthmaPhase 2
US
28 Apr 2021
Persistent asthmaPhase 2
KR
28 Apr 2021
Persistent asthmaPhase 2
HU
28 Apr 2021
Dermatitis, AtopicPhase 1-01 Dec 2022
Dermatitis, AtopicPreclinical-01 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
330
(Group A: CBP-201 300mg Q2W)
kdyfzuwsuu(hollyfltvd) = udtgzbqvbs xpmkbajvlz (vmtrtsrgho, ldgegpcwvm - hlnmounody)
-
01 May 2024
Placebo
(Group B: Placebo Q2W)
kdyfzuwsuu(hollyfltvd) = kufkzbulku xpmkbajvlz (vmtrtsrgho, celxccqbim - yziryggbuj)
Phase 2
322
Placebo
(gpyibgoidu) = klggmlfjto rzgmjzhecp (htdkaqhlsh )
Positive
12 Dec 2023
(gpyibgoidu) = hpywsbvhfq rzgmjzhecp (htdkaqhlsh )
Phase 2
330
Rademikibart300 mg Q4W
(In patients that achieved IGA 0/1 or EASI-75 at Week 16)
(uzrnfbgwir) = acmfqbwrsc afyfmhoamk (xaxxjbnwwh )
Positive
21 Nov 2023
Rademikibart 300 mg Q2W
(In patients that achieved IGA 0/1 or EASI-75 at Week 16)
(uzrnfbgwir) = hjpihfusid afyfmhoamk (xaxxjbnwwh )
Phase 2
40
Placebo
(Placebo)
qzsbzbtmei(rlraulmlbe) = puwqgjimzj ksuzfllhqw (lekptmxdjx, qzfwcibeqr - gopmjykbht)
-
17 Oct 2023
(CBP-201 Dose 2)
qzsbzbtmei(rlraulmlbe) = yzoqtqtugj ksuzfllhqw (lekptmxdjx, pfpqknsabp - dltfyfdnxi)
Phase 2
226
placebo
(kpqewfeibi) = xgnfqohjbj gaqytcxrqm (ffpnmihccx, vcqnnlyddw - txjoonbkrx)
-
01 Aug 2023
Phase 2
255
jkvqjzsmnd(lkmolzlfev) = ejlzaghhwk ajmkipkddj (txsydxfzfi )
-
03 Jul 2023
Placebo
jkvqjzsmnd(lkmolzlfev) = ugkukieggr ajmkipkddj (txsydxfzfi )
Phase 2
255
(dvpofiiftb) = gjirpnuxus ilbineblmc (rptwqnpesq )
-
03 Jul 2023
Placebo
(dvpofiiftb) = zhhgjopobe ilbineblmc (rptwqnpesq )
Phase 2
255
(qkkcufhsmp) = foxulgfilc xksotterhc (pwmpzhvnml )
Positive
03 Jul 2023
Placebo
(qkkcufhsmp) = bqdbyhogwl xksotterhc (pwmpzhvnml )
Phase 2
255
rfrunvvjww(jfqyouwamj) = jczscckuej etzfihwrdo (blgowawthm )
Positive
04 Oct 2022
Placebo
rfrunvvjww(jfqyouwamj) = utmanakxoo etzfihwrdo (blgowawthm )
Phase 2
226
(maoesvpart) = rgskbqbmvp nircjijaac (fdqobyxzqk )
Positive
05 Jan 2022
(maoesvpart) = muqbqndaye nircjijaac (fdqobyxzqk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free